Director of Pharmaceutical Development
Nurix Therapeutics
Director of Pharmaceutical Development
Nurix Therapeutics
Drug discovery targeting ubiquitin E3 ligases
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.
Position:
Nurix Therapeutics, Inc. is seeking a highly experienced Director of Pharmaceutical Development. The role leads small molecule drug product development focused on oral and topical dosage forms. Responsibilities span QbD-based formulation and process development from early phase through commercial launch. The position requires strong cross-functional collaboration and hands-on CDMO management.
Responsibilities:
Formulation & Process Development
Scale-Up & Technology Transfer
Late-Stage Development & Regulatory
CDMO Management & Cross-Functional Leadership
Requirements
Core Competencies
Salary Range: $218,000 – 260,000
Location: This position is on site in the Brisbane, CA office.
Fit with Nurix Culture and Values:
Drug discovery targeting ubiquitin E3 ligases
Nurix Therapeutics develops drugs that use the body's own protein-degradation system to treat diseases. Its core approach is to control ubiquitin E3 ligases, enzymes that tag unwanted proteins for breakdown in cells. By modulating these ligases, Nurix aims to create therapeutics, especially small-molecule immuno-oncology agents, that can selectively remove disease-related proteins in cancer and other serious conditions. The company operates by discovering and developing drug candidates and earning revenue through partnerships, licensing, and potential future sales of its medicines. Unlike many biotech firms that target single proteins, Nurix focuses on the protein-degradation pathway to influence multiple disease processes through carefully designed molecules. The goal is to bring new cancer treatments and other therapies to patients by advancing its degrader-based drugs through research, collaboration, and development toward commercial use.
Explore more opportunities at Nurix Therapeutics